| 小分子干扰核糖核酸脂质体对乙型肝炎病毒的药效学研究 |
| |
| 引用本文： | 吴志军,杨宝峰,陈玉军,高晶,李郑武,王晴,徐岩,刘恒,丁字,于淼,李会成.小分子干扰核糖核酸脂质体对乙型肝炎病毒的药效学研究[J].中国药业,2008,17(5):6-7. |
| |
| 作者姓名： | 吴志军 杨宝峰 陈玉军 高晶 李郑武 王晴 徐岩 刘恒 丁字 于淼 李会成 |
| |
| 作者单位： | 1. 哈尔滨医科大学药学院,黑龙江,哈尔滨,150060
2. 哈药集团技术中心,黑龙江,哈尔滨,150020 |
| |
| 基金项目： | 黑龙江省自然科学基金
,
黑龙江省哈尔滨市科技攻关计划 |
| |
| 摘 要： | 目的利用HepG2．2．2．15细胞模型研究小分子干扰核糖核酸脂质体对乙型肝炎病毒（HBV）的抑制作用。方法在药物对细胞的最大无毒浓度下，依次设定4个浓度梯度，分别测定不同时间收集的培养液中的乙型表面抗原（HBsAg）和乙肝病毒脱氧核糖核酸（HBV—DNA）。结果第12天时质量浓度为5μg／mL的药物对HBV的HBsAg表达的抑制率达到了63％，抑制程度随药物质量浓度的升高，或时间的增加而提高；药物质量浓度为5μg／mL时对HBV—DNA的抑制率达到了85．46％，抑制程度随着药物质量浓度的上升而提高。结论药物对HBV的HBsAg表达的抑制作用具有明显的剂量效应和时间效应．对HBV—DNA的抑制作用也有很好的剂量效应；利用基因工程手段制备的双链小分子RNA脂质体制剂具有明显抑制HBV的HBsAg表达和抑制HBV—DNA复制的作用，为利用RNA干扰技术研究开发新型抗HBV药物创造了条件。
|
| 关 键 词： | 小分子干扰核糖核酸脂质体 乙型肝炎病毒 药效学 |
| 文章编号： | 1006-4931(2008)05-0006-02 |
| 修稿时间： | 2007年6月8日 |
Pharmacodynamic Study on Liposome of Small Molecular RNAi to Hepatitis B Virus |
| |
| Wu Zhijun,Yang Baofeng,Chen Yujun,Gao Jing,Li Zhengwu,Wang Qing,Xu Yan,Liu Heng,Ding Yu,Yu Miao,Li Huicheng.Pharmacodynamic Study on Liposome of Small Molecular RNAi to Hepatitis B Virus[J].China Pharmaceuticals,2008,17(5):6-7. |
| |
| Authors: | Wu Zhijun Yang Baofeng Chen Yujun Gao Jing Li Zhengwu Wang Qing Xu Yan Liu Heng Ding Yu Yu Miao Li Huicheng |
| |
| Institution: | Wu Zhijun^1, Yang Baofeng^1, Chert Yujun^1, Gao Jing^1, Li Zhengwu^2, Wang Qing^2, Xu Yah^2, Liu Heng^2, Ding Yu^2, Yu Miao^2, Li Huicheng^2 ( 1. College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China 150060; 2, Harbin Pharmaceutical Group R ＆ D Center, Harbin, Heilongjiang, China 150020) |
| |
| Abstract: | Objective To study the inhibitory effects of the liposome of small molecular RNAi to Hepatitis B virus by utilizing the HepG2.2. 2. 15 cell model. Methods Four different concentration testing groups under the maximum safe dosage were designed. The level of HBsAg and HBV- DNA in the cell culture were tested at the different time intervals. Results The ratio of inhibition to HBsAg and HBV-DNA was up to 63% and 85.46% with 5μg/mL concentration on 12 d after the treatment respectively. The inhibitory degree varied with the test dnlg concentrations. Conclusion The test drug has obviously inhibitive effects on hepatitis B virus with different dosages and time. This further proves that the liposome of small RNAi by gene recombinant technique has the obvious effects on hepatitis B, which creates a new conditions for developing new drug for anti- hepatitis B. |
| |
| Keywords: | liposome of small molecular RNAi hepatitis B virus pharmacodynamics |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
